Just Published: Adjuvant pembrolizumab after resected stage III melanoma led to a 5-year recurrence-free survival of 55.4%, compared with 38.3% in patients treated with placebo. Read more in NEJM Evidence: https://eviden.cc/3x6Wg6l #ESMO22 | The New England Journal of Medicine

2.4K views · 65 reactions | Patients with stage III or IV melanoma can benefit from adjuvant pembrolizumab. Whether outcomes with neoadjuvant plus adjuvant pembrolizumab would be better than those with adjuvant therapy alone is unknown. New research findings are summarized in a short video. https://nej.md/3YaD6qN | The New England Journal of Medicine | Facebook

Current standard immunotherapy with medications such as keytruda, opdivo or yervoy results vary depending on many factors with a 24 month survival rate of 53% in melanoma, a better responding cancer, with occasional cures. These therapies are expensive, have side effects and still are lacking in results. We now have made a quantum leap in cancer treatment by adding ablation with vaccine adjuvants, completely blowing away the results of standard immunotherapy. https://williamscancerinstitute.com

Don't miss out on your chance to discover the latest FDA-approved combination of Keytruda and chemotherapy treatment. Learn From Experts On: ✔️ How Keytruda Works With Chemotherapy to Fight Mesothelioma ✔️What Patients Should Expect ✔️Clinical Trial Results and Patient Eligibility Factors Sign up now! https://buff.ly/3AR0hAS | The Mesothelioma Center | Facebook